ZA201005210B - Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity - Google Patents

Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity

Info

Publication number
ZA201005210B
ZA201005210B ZA2010/05210A ZA201005210A ZA201005210B ZA 201005210 B ZA201005210 B ZA 201005210B ZA 2010/05210 A ZA2010/05210 A ZA 2010/05210A ZA 201005210 A ZA201005210 A ZA 201005210A ZA 201005210 B ZA201005210 B ZA 201005210B
Authority
ZA
South Africa
Prior art keywords
indolyl
inhibitory activity
checkpoint kinase
pyridone derivatives
pyridone
Prior art date
Application number
ZA2010/05210A
Other languages
English (en)
Inventor
Simon Bedford
Andrea Fiumana
Stephen Stokes
Nicolas Noel Foloppe
Paul Webb
Martin James Drysdale
Original Assignee
Vernalis (R & D) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0801090.2A external-priority patent/GB0801090D0/en
Priority claimed from GBGB0818695.9A external-priority patent/GB0818695D0/en
Application filed by Vernalis (R & D) Ltd filed Critical Vernalis (R & D) Ltd
Publication of ZA201005210B publication Critical patent/ZA201005210B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2010/05210A 2008-01-22 2010-07-21 Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity ZA201005210B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0801090.2A GB0801090D0 (en) 2008-01-22 2008-01-22 New chemical compounds
GBGB0818695.9A GB0818695D0 (en) 2008-10-11 2008-10-11 New chemical compounds
PCT/GB2009/000149 WO2009093012A1 (en) 2008-01-22 2009-01-20 Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity

Publications (1)

Publication Number Publication Date
ZA201005210B true ZA201005210B (en) 2011-03-30

Family

ID=40377594

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/05210A ZA201005210B (en) 2008-01-22 2010-07-21 Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity

Country Status (17)

Country Link
US (5) US8916591B2 (OSRAM)
EP (1) EP2294065B1 (OSRAM)
JP (1) JP5386508B2 (OSRAM)
CN (1) CN101970424B (OSRAM)
AU (1) AU2009207478B2 (OSRAM)
BR (1) BRPI0906495B8 (OSRAM)
CA (1) CA2712959C (OSRAM)
DK (1) DK2294065T3 (OSRAM)
EA (1) EA021464B1 (OSRAM)
ES (1) ES2461799T3 (OSRAM)
IL (1) IL206808A (OSRAM)
MX (1) MX2010007525A (OSRAM)
NZ (1) NZ586756A (OSRAM)
PL (1) PL2294065T3 (OSRAM)
PT (1) PT2294065E (OSRAM)
WO (1) WO2009093012A1 (OSRAM)
ZA (1) ZA201005210B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5386508B2 (ja) 2008-01-22 2014-01-15 ヴァーナリス アールアンドディー リミテッド インドリル−ピリドン誘導体類
GB0912499D0 (en) * 2009-07-18 2009-08-26 Vernalis R&D Ltd Indopyl-pyridone derivatives
CN102933572B (zh) 2010-04-07 2015-01-07 霍夫曼-拉罗奇有限公司 吡唑-4-基-杂环基-甲酰胺化合物及其使用方法
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
BR112014007203A2 (pt) 2011-09-27 2017-06-13 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
CR20170345A (es) * 2015-01-28 2017-09-29 Bayer Pharma Aktiengesellchaft Derivados de 4h-pirrol[3,2-c]piridin-4-ona
SG11202005700SA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co Amide substituted indole compounds useful as tlr inhibitors
KR20210038911A (ko) * 2018-07-24 2021-04-08 에피자임, 인코포레이티드 Smarca2 길항제로서 유용한 피리딘-2-온 화합물
US10253606B1 (en) 2018-07-27 2019-04-09 Upwing Energy, LLC Artificial lift
US10280721B1 (en) 2018-07-27 2019-05-07 Upwing Energy, LLC Artificial lift
US10787873B2 (en) 2018-07-27 2020-09-29 Upwing Energy, LLC Recirculation isolator for artificial lift and method of use
US10370947B1 (en) * 2018-07-27 2019-08-06 Upwing Energy, LLC Artificial lift
WO2020038460A1 (zh) * 2018-08-24 2020-02-27 南京药捷安康生物科技有限公司 一种新型的喹啉衍生物抑制剂
US11686161B2 (en) 2018-12-28 2023-06-27 Upwing Energy, Inc. System and method of transferring power within a wellbore
EP4036086A1 (en) * 2019-09-24 2022-08-03 Transthera Sciences (Nanjing), Inc. Heterocyclic derivative and use thereof
JP2025523514A (ja) * 2022-06-24 2025-07-23 エナラーレ セラピューティクス インコーポレイテッド 神経性換気不全の処置方法
CN115594634B (zh) * 2022-10-26 2024-10-01 浙江工业大学 一种连续化制备4-硝基吡唑的新工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030844A2 (en) * 2001-03-28 2005-08-31 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
EP1441725A1 (en) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
JP2006526654A (ja) 2003-06-05 2006-11-24 メルク　エンド　カムパニー　インコーポレーテッド 置換インドールおよび置換インドールの調製方法
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2007084135A2 (en) * 2005-01-28 2007-07-26 Merck & Co., Inc. Inhibitors of checkpoint kinases
EP1891048A1 (en) * 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
WO2008007122A2 (en) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
WO2008025526A1 (en) 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
JP5386508B2 (ja) 2008-01-22 2014-01-15 ヴァーナリス アールアンドディー リミテッド インドリル−ピリドン誘導体類
US8778972B2 (en) * 2009-05-15 2014-07-15 Novartis Ag 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1

Also Published As

Publication number Publication date
US20200361905A1 (en) 2020-11-19
PT2294065E (pt) 2014-05-15
IL206808A0 (en) 2010-12-30
EP2294065A1 (en) 2011-03-16
CA2712959C (en) 2015-06-23
EP2294065B1 (en) 2014-03-19
BRPI0906495A2 (pt) 2015-07-14
NZ586756A (en) 2012-04-27
DK2294065T3 (da) 2014-04-28
AU2009207478B2 (en) 2013-11-21
BRPI0906495B8 (pt) 2021-05-25
JP5386508B2 (ja) 2014-01-15
US20180244652A1 (en) 2018-08-30
AU2009207478A1 (en) 2009-07-30
CA2712959A1 (en) 2009-07-30
US20110021498A1 (en) 2011-01-27
MX2010007525A (es) 2010-08-18
US8916591B2 (en) 2014-12-23
EA201001197A1 (ru) 2011-04-29
WO2009093012A1 (en) 2009-07-30
CN101970424B (zh) 2013-06-12
US9604975B2 (en) 2017-03-28
US20170298043A1 (en) 2017-10-19
US20150099736A1 (en) 2015-04-09
CN101970424A (zh) 2011-02-09
IL206808A (en) 2015-08-31
EA021464B1 (ru) 2015-06-30
JP2011510055A (ja) 2011-03-31
US10696652B2 (en) 2020-06-30
PL2294065T3 (pl) 2014-11-28
ES2461799T3 (es) 2014-05-21
BRPI0906495A8 (pt) 2015-10-06
BRPI0906495B1 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
ZA201005210B (en) Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
EP2119703A4 (en) NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
GB201000648D0 (en) Phosphodiesterase 10 inhibitors
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
EP2211615A4 (en) PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
EP2200436A4 (en) SUBSTITUTED PYRIMIDINYLAMINE AS PROTEIN KINASENHEMMER
ZA201004243B (en) Benzofuropyrimidinones as protein kinase inhibitors
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
PL2610256T3 (pl) Pochodne pirymidyny jako inhibitory kinaz białkowych
IL184674A0 (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
SI2154967T1 (sl) Derivati pirimidina
EP2222166A4 (en) INHIBITORS OF HETEROCYCLIC KINASES
IL197714A0 (en) 2-pyridinecarboxamide derivative having gk-activating activity
HU0900798D0 (en) 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
ZA201008878B (en) Naphthyridiniones as aurora kinase inhibitors
IL202301A0 (en) Tetrahydroisoquinolin-1-one derivative or salt thereof
EP1979493A4 (en) METHODS OF MEASURING THE ACTIVITY OF A KINASE
ZA201002580B (en) Heterocyclic derivatives
ZA200908943B (en) Pyrazolopyrimidinone kinase inhibitor
GB0603522D0 (en) Kinase inhibition
IL209403A0 (en) Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity
GB0606238D0 (en) Kinase inhibition
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors